The Resolution Therapeutics team will be at AASLD, Denver, to discuss our clinical program. The above video provides Q&A insights into our program, presented by Cliff Brass (CMO) and Lara Campana (SVP, Head of Research & Translational Science)
AASLD 2026 Q&A
More Stories
05/11/2026
Resolution Therapeutics Announces Positive Interim Phase I/II EMERALD Data for Regenerative Macrophage Therapy RTX001 in End-Stage Liver Disease
Six-month interim data showed a 42% relative risk reduction in death, liver transplant and hepatic decompensation versus an external control RTX001 was well-tolerated, with no infusion-related serious adverse reactions; biomarker analyses demonstrated suppression of key inflammatory pathways and reduced fibrogenesis Positive interim results support advancement of RTX001 towards a planned U.S. pivotal trial, with a pre-IND meeting with the FDA scheduled December 2026
16/10/2026
Could Regenerative Macrophage Therapy (RMT) change the future of treatment for patients with cirrhosis?
“The EMERALD study offers the possibility of incorporating macrophage-based cell therapy into our day-to-day treatment of patients with cirrhosis.” Dr. Manuel Rodríguez-Perálvarez
06/10/2026
Resolution Therapeutics to present interim EMERALD data on RTX001 as a late-breaker at AASLD 2026
Interim data from Phase I/II EMERALD study for RTX001, Resolution’s engineered Regenerative Macrophage Therapy, accepted as late-breaking presentation. Dr. Lara Campana to present preclinical data on intravenous Regenerative Macrophage Therapy for decompensated cirrhosis.